FDA
NRx Pharmaceuticals Achieves Data Lock in Phase 2B/3 Trial of NRX-101
After ‘Positive’ FDA Meeting, Cybin Looks Ahead to Phase 3 CYB003 Program
FDA Green-Lights Expedited Review Path for Cybin’s CYB003 Psilocybin Molecule
Cybin: CYB003 Achieves ‘Primary Efficacy Endpoint’ in Phase 2 Study
